US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRO Concept

1,595.65

+53.463.47%

Number of Gainers:2

Number of Losers:- -

Number of Flat:1

PE:- -

High:1,614.51

Open:1,555.20

Low:1,548.76

Close:1,542.19

Volume:2.87M

Turnover:512.85M

Market Cap:40.46B

Float Cap:38.73B

Loading ...

Joseph W. LaPlume, EVP of Corp Strategy & Development, Reports Disposal of Common Shares in Charles River Laboratories International Inc

Interim results for six months ended 30 June 2025

PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns

RBC says PTC Therapeutics CRL may signal difficulty for Biohaven

PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital

Precigen Enters Commercial Supply Agreement with Catalent

IQVIA and Veeva Forge Long-term Partnerships, Resolve All Legal Disputes

IQVIA and Veeva Announce Long-Term Clinical and Commercial Partnerships and Resolution of All Disputes

THOMSON REUTERS

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

Applied Therapeutics Reports Q2 Loss

IQVIA Holdings (IQV) Enters Partnership With Kexing Biopharm To Enhance Drug Development

Simply Wall St.

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

BRIEF-Kexing Biopharm Enters Strategic Partnership With IQVIA

Kexing Biopharm Enters Strategic Partnership With IQVIA to Accelerate Global Expansion

THOMSON REUTERS

Joseph W. LaPlume, EVP of Corp Strategy & Develop, Reports Disposal of Charles River Laboratories Common Shares

Charles River Labs Is Maintained at Equal-Weight by Barclays

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Charles River price target raised to $175 from $170 at BofA

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4530/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4530","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","market":"US","secType":"PLATE","nameCN":"CRO Concept","latestPrice":1595.649,"timestamp":1755892799999,"preClose":1542.1923,"halted":0,"volume":2873958,"delay":0,"changeRate":0.034663,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":53.456787,"latestTime":"08-22 16:00:00 EDT","open":1555.2047,"high":1614.5065,"low":1548.755,"amount":512846388.069609,"amplitude":0.042635,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756108800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.284359,"peRate":33.438715,"turnoverRate":0.01368,"increases":2,"decrements":0,"flats":0,"marketCap":40460321280,"floatMarketCap":38732718080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","high":1614.5065,"amplitude":0.042635,"preClose":1542.1923,"low":1548.755,"pbRate":"4.284359","latestPrice":1595.649,"volume":2873958,"delay":0,"open":1555.2047,"prevYearClose":1673.3123,"prevWeekClose":1585.2716,"prevMonthClose":1574.2637,"prevQuarterClose":1348.1335,"fiveDayClose":1585.2716,"twentyDayClose":1677.9094,"sixtyDayClose":1192.0001,"secType":"PLATE","market":"US","turnoverRate":0.01368,"peRate":33.438715,"marketCap":40460321280,"floatMarketCap":38732718080,"timestamp":1755892799999,"nameCN":"CRO Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4530\",,,,undefined,":{"bkCode":"BK4530","up":2,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4530\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2561848485","title":"Joseph W. LaPlume, EVP of Corp Strategy & Development, Reports Disposal of Common Shares in Charles River Laboratories International Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2561848485","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561848485?lang=en_us&edition=fundamental","pubTime":"2025-08-21 04:46","pubTimestamp":1755722777,"startTime":"0","endTime":"0","summary":"Joseph W. LaPlume, EVP of Corp Strategy & Development, Reports Disposal of Common Shares in Charles River Laboratories International Inc. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL9wSv21:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","LU1815336091.USD","LU0390134368.USD","BK4585","LU0757428866.USD","BK4588","BK4530","BK4121"],"gpt_icon":0},{"id":"2560124064","title":"Interim results for six months ended 30 June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2560124064","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560124064?lang=en_us&edition=fundamental","pubTime":"2025-08-20 14:00","pubTimestamp":1755669600,"startTime":"0","endTime":"0","summary":"OSB GROUP PLCInterim report for the six months ended 30 June 2025 LEI: 213800ZBKL9BHSL2K459 20 August 2025 OSB GROUP PLC (OSBG or the Group), the specialist lending and retail savings group, announces","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/20/3136136/0/en/Interim-results-for-six-months-ended-30-June-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","LU2125910336.SGD","BK4107","ESG","BK4141","HCI","LU1923622291.USD","PPD","LU2211814178.USD","BK4109","LU1721429402.USD","LU1992135399.USD","ERC","LCR","BK4023","LU2322448791.USD","PD","LU1712237335.SGD","LU1923621640.USD","BK4530","BK4561","NIM","LU2125909247.SGD","LU1169589451.USD","TNAV","LU1892829315.USD","POCI","LU2272731600.USD","FCA","PRA","ECL","HPI","LU1721429741.USD","BK4597","LU2125909759.SGD","LU2125910179.SGD","LU2272731782.SGD","LU2433249047.HKD","LU2473716301.USD","LU1169590202.USD","FSCS","LU0323240290.USD","OSB","LU2322448957.HKD","PRS","RMBS","UK","BK4121"],"gpt_icon":0},{"id":"2560113698","title":"PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2560113698","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560113698?lang=en_us&edition=fundamental","pubTime":"2025-08-19 23:20","pubTimestamp":1755616800,"startTime":"0","endTime":"0","summary":"FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another controlled trial.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/19/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/19/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/08/47212794/ptc-therapeutics-faces-fda-rejection-on-rare-disease-treatment-over-efficacy-concerns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["PTC","BK4535","LU2362541513.USD","BK4023","LU0390134368.USD","BK4130","LU1721428347.USD","FA","BK4585","LU1815336091.USD","LU2362540622.SGD","BK4554","LU2506952410.USD","LU1951198990.SGD","LU2362541273.HKD","LU2506952337.HKD","BK4576","PTCT","CRL","BK4121","BK4539","LU1923623000.USD","LU0320765992.SGD","LU1951200564.SGD","LU2477742899.HKD","BK4530","LU0889565916.HKD","BK4139","BK4588","LU0757428866.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2560118336","title":"RBC says PTC Therapeutics CRL may signal difficulty for Biohaven","url":"https://stock-news.laohu8.com/highlight/detail?id=2560118336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560118336?lang=en_us&edition=fundamental","pubTime":"2025-08-19 22:40","pubTimestamp":1755614420,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev notes that PTC Therapeutics (PTCT) received a complete response letter for vatiquinone in Friedreich’s ataxia f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-says-ptc-therapeutics-crl-may-signal-difficulty-for-biohaven-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-says-ptc-therapeutics-crl-may-signal-difficulty-for-biohaven-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2362541513.USD","BK4554","PTCT","LU2362541273.HKD","LU0708994859.HKD","LU1267930573.SGD","LU0029864427.USD","LU0320765992.SGD","BK4121","CRL","LU1951200564.SGD","LU0310800379.SGD","LU2506952410.USD","LU0128525929.USD","BK4139","LU0889565916.HKD","BK4576","BK4588","LU0757428866.USD","LU1923623000.USD","LU1951198990.SGD","LU2506952337.HKD","BK4207","LU0109394709.USD","LU2477742899.HKD","BK4585","BK4023","LU2362540622.SGD","LU0390134368.USD","PTC","LU1721428347.USD","LU1815336091.USD","BK4530"],"gpt_icon":0},{"id":"2560451190","title":"PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2560451190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560451190?lang=en_us&edition=fundamental","pubTime":"2025-08-19 22:35","pubTimestamp":1755614111,"startTime":"0","endTime":"0","summary":"PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s ataxia, with the FDA sta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ptc-therapeutics-crl-expected-focus-moves-to-sephience-says-rbc-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ptc-therapeutics-crl-expected-focus-moves-to-sephience-says-rbc-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","BK4588","LU1267930573.SGD","LU1815336091.USD","PTCT","LU0889565916.HKD","BK4576","LU0029864427.USD","LU0310800379.SGD","PTC","BK4530","LU2506952410.USD","LU2362541513.USD","BK4585","LU1951198990.SGD","LU0128525929.USD","LU1951200564.SGD","LU0757428866.USD","BK4554","BK4207","LU0320765992.SGD","LU0109394709.USD","LU0390134368.USD","LU2506952337.HKD","LU1721428347.USD","BK4121","LU2362541273.HKD","LU2477742899.HKD","LU1923623000.USD","CRL","BK4139","LU2362540622.SGD","LU0708994859.HKD"],"gpt_icon":0},{"id":"2560136672","title":"Precigen Enters Commercial Supply Agreement with Catalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2560136672","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560136672?lang=en_us&edition=fundamental","pubTime":"2025-08-19 05:31","pubTimestamp":1755552667,"startTime":"0","endTime":"0","summary":"Precigen ( ($PGEN) ) has shared an update. On August 13, 2025, Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, In...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/precigen-enters-commercial-supply-agreement-with-catalent?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/precigen-enters-commercial-supply-agreement-with-catalent?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","PGEN","BK4007","BK4530","BK4139","CTLT"],"gpt_icon":0},{"id":"2560900087","title":"IQVIA and Veeva Forge Long-term Partnerships, Resolve All Legal Disputes","url":"https://stock-news.laohu8.com/highlight/detail?id=2560900087","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560900087?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:01","pubTimestamp":1755522083,"startTime":"0","endTime":"0","summary":"IQVIA Holdings Inc. and Veeva Systems have announced global clinical and commercial partnerships, resolving all pending legal disputes between the two companies. The long-term agreement allows customers to seamlessly use software, data, technology, and service offerings from both companies. This collaboration aims to enhance clinical development and commercial operations by integrating IQVIA's clinical data management and technology solutions with Veeva's software products. The partnership is expected to accelerate clinical trials and improve access to innovations for patients, benefiting joint customers in the industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IQVIA Holdings Inc. published the original content used to generate t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL5XYls1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU0130518102.USD","LU0980610538.SGD","LU0058720904.USD","LU0289739699.SGD","LU0198837287.USD","LU0130103400.USD","BK4121","LU0477156953.USD","VEEV","BK4528","BK4534","LU0648001328.SGD","LU1201861249.SGD","BK4530","LU1989764748.USD","LU1201861165.SGD","LU0170899867.USD","LU0477156797.USD","LU0130517989.USD","LU1791710582.SGD","LU1989764664.SGD","IQV","LU1791710400.SGD","BK4167","BK4585","LU0648000940.SGD","LU0882574055.USD","BK4504","LU0130102774.USD","BK4613","LU1261432733.SGD","BK4588","LU0528227936.USD"],"gpt_icon":0},{"id":"2560590078","title":"IQVIA and Veeva Announce Long-Term Clinical and Commercial Partnerships and Resolution of All Disputes","url":"https://stock-news.laohu8.com/highlight/detail?id=2560590078","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560590078?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:00","pubTimestamp":1755522002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUA130858:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0266013472.USD","LU0648000940.SGD","BK4528","LU1989764664.SGD","LU1201861249.SGD","LU0648001328.SGD","LU0130518102.USD","LU0130517989.USD","BK4613","BK4167","LU0198837287.USD","VEEV","BK4530","LU0477156953.USD","LU0130103400.USD","LU0980610538.SGD","LU0170899867.USD","BK4534","LU0289739699.SGD","LU1791710400.SGD","LU0058720904.USD","IQV","BK4588","LU1261432733.SGD","LU0528227936.USD","BK4121","LU1791710582.SGD","LU0882574055.USD","LU1989764748.USD","LU0130102774.USD","BK4504","LU1201861165.SGD","BK4585","LU0477156797.USD"],"gpt_icon":0},{"id":"2559019964","title":"Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2559019964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559019964?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:35","pubTimestamp":1755203700,"startTime":"0","endTime":"0","summary":"FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug.  14, 2025  (GLOBE N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133933/32445/en/Minerva-Neurosciences-Provides-Business-Updates-and-Second-Quarter-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","NERV","LU0390134368.USD","BK4588","BK4121","BK4585","LU1815336091.USD","CRL","LU0757428866.USD","PSP","BK4139"],"gpt_icon":0},{"id":"2559951617","title":"Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL","url":"https://stock-news.laohu8.com/highlight/detail?id=2559951617","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559951617?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:15","pubTimestamp":1755170142,"startTime":"0","endTime":"0","summary":"Unicycive has requested a Type A meeting with the FDA to discuss resolution of the CRL received in June in regard to its New Drug Application for O...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-requests-type-a-meeting-with-fda-to-discuss-crl-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-requests-type-a-meeting-with-fda-to-discuss-crl-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4530","LU0390134368.USD","BK4588","BK4121","BK4585","BK4007","LENZ","UNCY","LU1815336091.USD","CRL","LU0757428866.USD","BK4539","BK4139"],"gpt_icon":0},{"id":"2559982203","title":"Applied Therapeutics Reports Q2 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2559982203","media":"Motley Fool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559982203?lang=en_us&edition=fundamental","pubTime":"2025-08-14 06:12","pubTimestamp":1755123120,"startTime":"0","endTime":"0","summary":"GAAP earnings per share of $0.15 beat consensus estimates despite continued operating losses.No revenue  was recognized for Q2 2025, down from $0.14 million  in Q2 2024.Cash and cash equivalents  fell sharply to $30.4 million as of June 30, 2025.","market":"nz","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2025/08/13/applied-therapeutics-reports-q2-loss/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4530","BK4539","LU0390134368.USD","LU0757428866.USD","BK4139","LENZ","BK4007","BK4121","BK4588","BK4585","LU1815336091.USD","CRL"],"gpt_icon":0},{"id":"2559621295","title":"IQVIA Holdings (IQV) Enters Partnership With Kexing Biopharm To Enhance Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621295","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621295?lang=en_us&edition=fundamental","pubTime":"2025-08-13 01:53","pubTimestamp":1755021200,"startTime":"0","endTime":"0","summary":"IQVIA Holdings (IQV) recently forged a strategic partnership with Kexing Biopharm, aiming to bolster the clinical development and market integration of innovative therapeutics globally. Over the last quarter, IQVIA's stock price rose by 19.52%, aligning closely with broader market trends. This partnership has likely contributed positively by highlighting the company's commitment to international expansion. Concurrently, the broader market optimism driven by expectations of potential Federal...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-holdings-iqv-enters-partnership-with-kexing-biopharm-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0648001328.SGD","LU0477156953.USD","LU1989764664.SGD","LU1201861165.SGD","LU0648000940.SGD","LU0130518102.USD","BK4121","LU0528227936.USD","LU0130517989.USD","LU0980610538.SGD","LU0130103400.USD","LU0198837287.USD","LU0477156797.USD","LU1261432733.SGD","LU0130102774.USD","BK4585","BK4588","LU1791710400.SGD","LU0882574055.USD","LU1201861249.SGD","LU1791710582.SGD","LU1989764748.USD","IQV","BK4530"],"gpt_icon":0},{"id":"2558649258","title":"Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649258","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649258?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996700,"startTime":"0","endTime":"0","summary":"FDA Accepted the Company’s Response to the CRL for CARDAMYST (etripamil) Nasal Spray; New PDUFA Target Date ofDecember 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3131577/0/en/Milestone-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Regulatory-and-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","BK4585","BK4530","CRL","BK4121","BK4588","LU0757428866.USD","LU1815336091.USD"],"gpt_icon":0},{"id":"2558965586","title":"BRIEF-Kexing Biopharm Enters Strategic Partnership With IQVIA","url":"https://stock-news.laohu8.com/highlight/detail?id=2558965586","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558965586?lang=en_us&edition=fundamental","pubTime":"2025-08-11 17:30","pubTimestamp":1754904611,"startTime":"0","endTime":"0","summary":"BRIEF-Kexing Biopharm Enters Strategic Partnership With IQVIAAug 11 (Reuters) - Kexing Biopharm Co Ltd 688136.SS:KEXING BIOPHARM ENTERS STRATEGIC PARTNERSHIP WITH IQVIA TO ACCELERATE GLOBAL EXPANSIONSource text: ID:nPrewyp7YaFurther company coverage: 688136.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nFWN3U10DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989764748.USD","LU0648001328.SGD","LU1261432733.SGD","BK4585","BK0239","LU0130517989.USD","LU0130103400.USD","BK4530","IQV","LU0477156953.USD","LU1201861165.SGD","LU0477156797.USD","LU0648000940.SGD","LU1791710582.SGD","LU0528227936.USD","LU1791710400.SGD","LU0980610538.SGD","LU0882574055.USD","688136","LU0130518102.USD","LU0130102774.USD","BK4121","BK4588","LU1201861249.SGD","LU1989764664.SGD","LU0198837287.USD"],"gpt_icon":0},{"id":"2558653376","title":"Kexing Biopharm Enters Strategic Partnership With IQVIA to Accelerate Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2558653376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558653376?lang=en_us&edition=fundamental","pubTime":"2025-08-11 17:20","pubTimestamp":1754904037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nFWN3U10DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","LU1201861249.SGD","LU0130518102.USD","LU0477156797.USD","BK4121","688136","BK0239","LU0980610538.SGD","LU1791710400.SGD","LU0130517989.USD","LU0130103400.USD","LU0198837287.USD","LU0130102774.USD","LU1791710582.SGD","LU0648000940.SGD","LU1989764664.SGD","LU1201861165.SGD","LU0528227936.USD","BK4530","LU1261432733.SGD","LU0648001328.SGD","BK4585","BK4588","IQV","LU0477156953.USD","LU1989764748.USD"],"gpt_icon":0},{"id":"2558728135","title":"Joseph W. LaPlume, EVP of Corp Strategy & Develop, Reports Disposal of Charles River Laboratories Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2558728135","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558728135?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:19","pubTimestamp":1754684371,"startTime":"0","endTime":"0","summary":"Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories International Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL9DZLq5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","BK4530","CRL","LU0390134368.USD","BK4585","BK4588","BK4121","LU0757428866.USD"],"gpt_icon":0},{"id":"2557698785","title":"Charles River Labs Is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2557698785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557698785?lang=en_us&edition=fundamental","pubTime":"2025-08-07 21:23","pubTimestamp":1754572980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 07, 2025 09:23 ET (13:23 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","BK4121","LU0390134368.USD","CRL","BK4585","LU1815336091.USD","BK4530","BK4588"],"gpt_icon":0},{"id":"2557566847","title":"Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557566847","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557566847?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., Aug.  07, 2025  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ann","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129162/0/en/Replimune-Reports-Fiscal-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HCC","LU0390134368.USD","BK4006","LU0757428866.USD","LU1815336091.USD","BK4530","BTC","BK4121","CRL","BK4585"],"gpt_icon":0},{"id":"2557301860","title":"Charles River price target raised to $175 from $170 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2557301860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557301860?lang=en_us&edition=fundamental","pubTime":"2025-08-07 02:05","pubTimestamp":1754503528,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Charles River (CRL) to $175 from $170 and keeps a Neutral rating on the shares. The company’s Q2 sales resul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-price-target-raised-to-175-from-170-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-price-target-raised-to-175-from-170-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0757428866.USD","BK4588","BK4530","LU1815336091.USD","CRL","BK4121","LU0390134368.USD","BK4585"],"gpt_icon":0},{"id":"2557306045","title":"Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2557306045","media":"Benzinga","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557306045?lang=en_us&edition=fundamental","pubTime":"2025-08-07 00:50","pubTimestamp":1754499009,"startTime":"0","endTime":"0","summary":"Charles River lifts earnings guidance after Q2 beat, citing biotech demand stability, solid DSA performance, and easing regulatory headwinds.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/08/46912751/charles-river-sees-limited-impact-from-nih-cuts-tariffs-drug-pricing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","BK4585","CRL","LU0390134368.USD","LU0757428866.USD","LU1815336091.USD","BK4121","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}